OR WAIT 15 SECS
Lonza is expanding parenteral dosage development capability and capacity in its Drug Product Services (DPS) sector at the company’s Basel, Switzerland facility.
On Aug. 24, 2017, Lonza announced the expansion of parenteral dosage development in its Drug Product Services (DPS) sector. The expansion will increase DPS capability and capacity at the company’s facility in Basel, Switzerland, where more than 50 new positions will be created. The expansion includes new capabilities for drug-product process development.
In November 2016, DPS opened its laboratories with a focus on formulation development and drug product analytical development. After a recent audit from Swissmedic, the Swiss agency for therapeutic-product regulation, the facility was granted a good manufacturing practice (GMP) license, allowing for quality-control (QC) release and stability testing of drug products.
DPS provides services for parenteral dosage forms, including products for injection and infusion for intravenous, subcutaneous, and intraocular routes of administration. Specialized-service offerings include: particulate identification; characterization and quantification; excipient and surfactant characterization; extractables and leachables assessment; and container closure integrity testing.
In addition to this latest expansion, the $5.5-billion acquisition of Capsugel, a provider of oral dosage delivery technologies specializing in hard capsules, in July 2017 has advanced the company’s capabilities in both parenteral and oral drug-product development.